Litcius/Paper detail

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

2020Annals of Oncology250 citationsDOI

Topics & Concepts

PembrolizumabMedicineInternal medicineOncologyExpanded accessFood and drug administrationClinical trialImmunotherapyCancerPharmacologyCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians | Litcius